The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-07-18. Anything still debated is marked as such rather than presented as settled.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Duncan returns to the mansion, where the few remaining henchmen flee rather than face him. Now alone, Blut awaits Duncan but ends up decapitated while calling for someone to bring him Camille. Rescuing Camille, Duncan returns to Montana and treats her inside her cabin. Duncan awakens one morning inside the cabin to find newspaper clippings of the murder of a family spread around Camille's bed. He recognizes the images as a hit that he carried out, albeit with bad intel, something that has haunted him ever since. The only survivor of the family was a daughter, who grew up to be Camille. To assuage his guilty conscience he has been making anonymous donations to her ever since, and she tracked him down by following the money trail. Held at gunpoint by Camille, Duncan apologizes and tells her to close her mind and pull the trigger. However, she spares him, asking if they can determine who ordered her father dead, and he commits to help her.
=== London Hospital === Florey was unhappy working at London Hospital; he disliked the long daily commute from Chobham that put his experimental work at the mercy of the railway timetable. In the summer Howard and Ethel lived in a flat in Belsize Park so he could devote more time to his work. He wrote up the results of the research he had done in New York on lacteals and lymphatic capillaries, which was published in the Journal of Physiology in 1927. Florey then embarked on writing a thesis for a fellowship at Gonville and Caius College, Cambridge, where he became an unofficial fellow in 1926. His thesis on "Physiology and pathology of the circulation of the blood and lymph" was accepted, and his fellowship awarded in 1927. He also continued his work on the secretion of mucus. London Hospital's facilities for the laboratory animals he needed for his research were unsatisfactory, so these experiments were carried out at Oxford and Cambridge. However, he was able to study the lacteals in patients undergoing abdominal surgery.
== Applications == Although protactinium is situated in the periodic table between uranium and thorium, both of which have numerous applications, there are currently no uses for protactinium outside scientific research owing to its scarcity, high radioactivity, and high toxicity. 231Pa arises naturally from the decay of natural 235U, and artificially in nuclear reactors by the reaction 232Th + n → 231Th + 2n and the subsequent beta decay of 231Th. It was once thought to be able to support a nuclear chain reaction, which could in principle be used to build nuclear weapons; the physicist Walter Seifritz once estimated the associated critical mass as 750±180 kg. However, the possibility of criticality of 231Pa has since been ruled out. With the advent of highly sensitive mass spectrometers, an application of 231Pa as a tracer in geology and paleoceanography has become possible. In this application, the ratio of 231Pa to 230Th is used for radiometric dating of sediments which are up to 175,000 years old, and in modeling of the formation of minerals. In particular, its evaluation in oceanic sediments helped to reconstruct the movements of North Atlantic water bodies during the last melting of Ice Age glaciers. Some of the protactinium-related dating variations rely on analysis of the relative concentrations of several long-living members of the uranium decay chain – uranium, protactinium, and thorium, for example. These elements have 6, 5, and 4 valence electrons, thus favoring +6, +5, and +4 oxidation states respectively, and display different physical and chemical properties.
It causes similar alterations on EEG readings and sleep architecture as benzodiazepines and causes disturbances in sleep architecture on withdrawal as part of its rebound effect. Zopiclone reduces both delta waves (slow-wave sleep) and the number of high-amplitude delta waves whilst increasing low-amplitude waves. Zopiclone reduces the total amount of time spent in REM sleep as well as delaying its onset. In EEG studies, zopiclone significantly increases the energy of the beta frequency band, increasing stage 2. Zopiclone is less selective to the α1 site and has higher affinity to the α2 site than zaleplon. Zopiclone is therefore very similar pharmacologically to benzodiazepines.
Sources: en.wikipedia.org
There are 25 known isotopes of potassium, three of which occur naturally: 39K (93.3%), 40K (0.0117%), and 41K (6.7%) (by mole fraction). Naturally occurring 40K has a half-life of 1.250×109 years. It decays to stable 40Ar by electron capture or positron emission (11.2%) or to stable 40Ca by beta decay (88.8%). This decay results in a relatively higher concentration of Argon in the atmosphere. The decay of 40K to 40Ar is the basis of a common method for dating rocks. The conventional potassium–argon dating method depends on the assumption that the rocks contained no argon at the time of formation and that all the subsequent radiogenic argon (40Ar) was quantitatively retained. Minerals are dated by measurement of the concentration of potassium and the amount of radiogenic 40Ar that has accumulated. The minerals best suited for dating include biotite, muscovite, metamorphic hornblende, and volcanic feldspar; whole rock samples from volcanic flows and shallow instrusives can also be dated if they are unaltered. Apart from dating, potassium isotopes have been used as tracers in studies of weathering and for nutrient cycling studies because potassium is a macronutrient required for life on Earth. 40K occurs in natural potassium (and thus in some commercial salt substitutes) in sufficient quantity that large bags of those substitutes can be used as a radioactive source for classroom demonstrations. 40K is the radioisotope with the largest abundance in the human body. In healthy animals and people, 40K represents the largest source of radioactivity, greater even than 14C.
This reacts up to 400 fold faster than the original pair with a rate constant of 5.5 ± 0.6 × 105 M−1 s−1. This version is back reactive with the two previous generations of SpyTag/SpyCatcher reagents. SpyTag/SpyCatcher react with specificity even when in the presence of bacterial and mammalian cell environments.
== See also == Adatom Cryo-adsorption Dual-polarization interferometry Fluidized bed concentrator Hydrogen-bonded organic framework Kelvin probe force microscope Micromeritics Molecular sieve Polanyi adsorption Pressure swing adsorption Random sequential adsorption Segregation (materials science)
Ukraine claimed that the armored strength of the Russian Southern Group of Forces had decreased "significantly" to 650 tanks, including those damaged or otherwise disabled, and total number of AFVs deployed was "no more than" 1,850 vehicles.
== Publications == Feb 2017 - Imaging Mass Cytometry. Sept 2010 - Highly Multiparametric Analysis by Mass Cytometry. July 2009 - Mass Cytometry: Technique for Real Time Single Cell Multitarget Immunoassay based on Inductively Coupled Plasma Time-Of-Flight Mass Spectrometry Aug 2007 - Polymer‐Based Elemental Tags for Sensitive Bioassays. Sept 2002 - Reaction Cells and Collision Cells for ICP-MS: a tutorial review. May 2002 - A Sensitive and Quantitative Element-Tagged Immunoassay with ICPMS Detection. Feb 2002 - Detection of Ultratrace Phosphorus and Sulfur by Quadrupole ICPMS with Dynamic Reaction Cell. July 2001 - Reaction Chemistry and Collisional Processes in Multipole Devices for Resolving Isobaric Interferences in ICP–MS. Jan 2000 - A Dynamic Reaction Cell for Inductively Coupled Plasma Mass Spectrometry (ICP-DRC-MS). Part III. Optimization and Analytical Performance. Nov 1999 - A Dynamic Reaction Cell for Inductively Coupled Plasma Mass Spectrometry (ICP-DRC-MS). Part II. Reduction of Interferences Produced within the Cell. March 1999 - Theory, Design, and Operation of a Dynamic Reaction Cell for ICP-MS. Feb 1997 - Activation of Hydrogen and Methane by Thermalized FeO+ in the Gas Phase as Studied by Multiple Mass Spectrometric Techniques. A more complete listing of his publications can be found on Google Scholar
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.